Phase I Study of NC-6004 in Combination With 5-FU and Cetuximab as First-line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Latest Information Update: 17 Sep 2020
At a glance
- Drugs Cisplatin (Primary) ; Cetuximab; Fluorouracil
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Orient Europharma
- 14 Sep 2020 Status changed from recruiting to discontinued due to Strategy change .
- 10 Jul 2016 New trial record